EN | UA
EN | UA

Help Support

Back

Elagolix found efficacious for the treatment of endometriosis

Elagolix found efficacious for the treatment of endometriosis Elagolix found efficacious for the treatment of endometriosis
Elagolix found efficacious for the treatment of endometriosis Elagolix found efficacious for the treatment of endometriosis

What's new?

Elagolix could be consider a choice of treatment for endometriosis as it is well-tolerated and does not cause loss of bone density like other GnRH antagonists.

There has been an extensive search for developing medications which can be used to alleviate endometriosis-associated symptoms. Also, an already established medication, a new GnRH antagonist, elagolix, is in development. Its nonpeptide structure, allows it to be administered orally, which is its novelty to compared to other GnRH antagonists.

Many Phase I, II and III clinical trials were analyzed, through which the safety and efficacy of this new medication were evaluated.

According to the opinion of the researcher, as several medications have been put on the market, which gained popularity for the alleviation of endometriosis-associated symptoms. Elagolix has an advantage over established GnRH agonists, in that it does not lead to a ‘flare-up’ effect, it too, takes a toll on bone mineral density. However, studies have shown that this new oral GnRH antagonist is well tolerated, and have ‘mild or moderate’ the side effects. But there is a need for further studies in order to examine whether elagolix can compete with or even surpass established gold-standard medical treatments in this field, that directly compare elagolix to said treatments.

 

Source:

Expert Opin Pharmacother. 2017 Jul 24

Article:

Efficacy of elagolix in the treatment of endometriosis

Authors:

Perricos A, Wenzl R

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: